Whole blood inactivation

Purpose and goal

The project aims to develop a prototype for a medical device that stabilize the levels of labile biomarkers in whole blood. Labile biomarkers change after sampling which distorts the analytical results and impair the ability to make correct decisions. The goal is to enable accurate analysis of labile biomarkers so that the correct dose can be prescribed to minimize side effects and maximize the therapeutic effect.

Expected effects and result

The introduction of a thermal stabilization step in direct connection with the sampling allows more flexibility in sample handling because the sample no longer changes. Quick access to a fully equipped laboratory is not required and the samples can be shipped at room temperature to the analytical laboratory. The analytical results better reflect the actual levels of volatile biomarkers, which ultimately leads to better diagnoses and more effective treatment with fewer side effects.

Planned approach and implementation

The stabilization is done with a thermal method, with no additives, and is performed directly with the sample in a standard blood collection tube, a Vacutainer. In cooperation with an engineering company, various heating methodologies will be evaluated initially and based on the most promising technology a prototype will be built. The prototype is then used to produce an extended proof of concept in cooperation with various parties with an interest in volatile biomarkers.